Merck gets US FDA approval for Keytruda plus pemetrexed & platinum chemotherapy to treat unresectable advanced or metastatic MPM: Rahway, New Jersey Thursday, September 19, 2024, ...

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...

Despite the positive results, KEYTRUDA can cause severe or fatal immune-mediated adverse reactions in any organ system at any time during or after treatment. Based on its mechanism of action ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its strategic plan for a Phase 2 study for ...

Announces focus on therapeutic approach; resulting in a faster and more cost-effective path to approval SAN JOSE, Calif., Sept. 24, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Compan ...

FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer ...

Confirmed overall response rate (ORR) was 37.5% for pelareorep + paclitaxel and 13.3% for paclitaxel. As previously reported, ORRs at week 16 (the trial's primary endpoint) in the pelareorep + ...

Marinus Pharmaceuticals, Inc. , a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today is hosting an Investor and Analyst Day and will ...

The UK pharma industry association has launched legal action against a newly-introduced ... prices via a confidential 'patient access scheme' mechanism. The introduction of the additional price ...